GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hansoh Pharmaceutical Group Co Ltd (HKSE:03692) » Definitions » EV-to-Revenue

Hansoh Pharmaceutical Group Co (HKSE:03692) EV-to-Revenue : 7.33 (As of May. 01, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Hansoh Pharmaceutical Group Co EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Hansoh Pharmaceutical Group Co's enterprise value is HK$80,977 Mil. Hansoh Pharmaceutical Group Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$11,051 Mil. Therefore, Hansoh Pharmaceutical Group Co's EV-to-Revenue for today is 7.33.

The historical rank and industry rank for Hansoh Pharmaceutical Group Co's EV-to-Revenue or its related term are showing as below:

HKSE:03692' s EV-to-Revenue Range Over the Past 10 Years
Min: 3.61   Med: 8.89   Max: 24.37
Current: 7.33

During the past 8 years, the highest EV-to-Revenue of Hansoh Pharmaceutical Group Co was 24.37. The lowest was 3.61. And the median was 8.89.

HKSE:03692's EV-to-Revenue is ranked worse than
84.18% of 1024 companies
in the Drug Manufacturers industry
Industry Median: 2.35 vs HKSE:03692: 7.33

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2024-05-01), Hansoh Pharmaceutical Group Co's stock price is HK$17.40. Hansoh Pharmaceutical Group Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was HK$1.83. Therefore, Hansoh Pharmaceutical Group Co's PS Ratio for today is 9.49.


Hansoh Pharmaceutical Group Co EV-to-Revenue Historical Data

The historical data trend for Hansoh Pharmaceutical Group Co's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hansoh Pharmaceutical Group Co EV-to-Revenue Chart

Hansoh Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-Revenue
Get a 7-Day Free Trial 13.84 19.83 7.73 6.55 6.42

Hansoh Pharmaceutical Group Co Semi-Annual Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.73 - 6.55 - -

Competitive Comparison of Hansoh Pharmaceutical Group Co's EV-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Hansoh Pharmaceutical Group Co's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hansoh Pharmaceutical Group Co's EV-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hansoh Pharmaceutical Group Co's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Hansoh Pharmaceutical Group Co's EV-to-Revenue falls into.



Hansoh Pharmaceutical Group Co EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Hansoh Pharmaceutical Group Co's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=80977.420/11051.337
=7.33

Hansoh Pharmaceutical Group Co's current Enterprise Value is HK$80,977 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Hansoh Pharmaceutical Group Co's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was HK$11,051 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hansoh Pharmaceutical Group Co  (HKSE:03692) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Hansoh Pharmaceutical Group Co's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=17.40/1.833
=9.49

Hansoh Pharmaceutical Group Co's share price for today is HK$17.40.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was HK$1.83.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hansoh Pharmaceutical Group Co EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Hansoh Pharmaceutical Group Co's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Hansoh Pharmaceutical Group Co (HKSE:03692) Business Description

Traded in Other Exchanges
Address
287 Xiangke Road, Pudong New District, Shanghai, CHN, 201210
Hansoh Pharmaceutical Group Co Ltd is a research and development-driven pharmaceutical company in China. The company holds a broad, diversified drug portfolio in CNS diseases, oncology, anti-infectives, and diabetes. Further, it also focuses on metabolic diseases and anti-tumor. The majority of revenue is generated from the sale of pharmaceutical products in Mainland China.

Hansoh Pharmaceutical Group Co (HKSE:03692) Headlines

No Headlines